Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Hengrui Pharmaceuticals CoFRA:0BO -2.18%71 3-Year EBITDA Growth Rate is 27.20% as of Jun. 2026, which is 17% above its 10-year median of 23.20. GuruFocus rates FRA:0BO with a GF Score™ of 71/100 and a GF Value™ of €6.24 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 808 Drug Manufacturers companies, Jiangsu Hengrui Pharmaceuticals Co ranks better than 76.36% on this metric.
During the past 12 months, Jiangsu Hengrui Pharmaceuticals Co's average EBITDA Per Share Growth Rate was -2.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 27.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 8.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 9.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Jiangsu Hengrui Pharmaceuticals Co was 46.40% per year. The lowest was -12.00% per year. And the median was 23.20% per year.
Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Jiangsu Hengrui Pharmaceuticals Co 3-Year EBITDA Growth Rate Related Terms
FRA:0BO vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's 3-Year EBITDA Growth Rate falls into.
Jiangsu Hengrui Pharmaceuticals Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 27.20% mean?
Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO) has a 3-Year EBITDA Growth Rate of 27.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is 17% above median its historical median of 23.20. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #191 out of 808 companies in the Drug Manufacturers industry, placing it in the top 23.6%.
Is Jiangsu Hengrui Pharmaceuticals Co's 3-Year EBITDA Growth Rate too high?
Jiangsu Hengrui Pharmaceuticals Co's current 3-Year EBITDA Growth Rate of 27.20% is 17% above median its 10-year median of 23.20. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Jiangsu Hengrui Pharmaceuticals Co's value of 27.20% is 205.6% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #191 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #191 out of 808 companies for 3-Year EBITDA Growth Rate. This places Jiangsu Hengrui Pharmaceuticals Co in the top 24% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Jiangsu Hengrui Pharmaceuticals Co's value of 27.20% is 205.6% above this benchmark. While the company's 10-year median is 23.20 vs. the industry median of 8.90, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current 3-Year EBITDA Growth Rate of 27.20% is 205.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current 3-Year EBITDA Growth Rate is 27.20%, which is 17% above median its own 10-year median of 23.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.24, compared to a current price of €4.94 — trading 20.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 27.20%, which is 17% above median its 10-year median of 23.20 and 205.6% above the Drug Manufacturers industry median of 8.90. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO), the current 3-Year EBITDA Growth Rate is 27.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (FRA:0BO) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of €4.94 is trading 20.8% below its estimated GF Value™ of €6.24.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for FRA:0BO:
3-Year EBITDA Growth Rate: 27.20% (17% above median its 10-year median of 23.20)
GF Value™: €6.24 vs. price of €4.94 (20.8% below fair value)
Industry Position: 205.6% above the Drug Manufacturers median (#191 of 808)
No single metric tells the full story. See the FRA:0BO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
71GF Score
Get the complete analysis for FRA:0BO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0BO has been successfully added to your 
